Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2000 Feb;91(2):213–222. doi: 10.1111/j.1349-7006.2000.tb00934.x

Interrelationships between Cellular Nucleotide Excision Repair, Cisplatin Cytotoxicity, HER‐2/neu Gene Expression, and Epidermal Growth Factor Receptor Level in Non‐small Cell Lung Cancer Cells

Chun‐Ming Tsai 1,2,✉, Kuo‐Ting Chang 1, Lan Li 3, Reury‐Perng Perng 2, Li‐Ying Yang 3
PMCID: PMC5926326  PMID: 10761709

Abstract

Nucleotide excision repair (NER) is a major repair mechanism for DNA lesions induced by cisplatin. Overexpressions of epidermal growth factor receptor (EGFR) and HER‐2/neu have been reported to affect the sensitivity of certain human cancer cells to cisplatin, presumably by modification of DNA repair activity through interference with NER. Using an in vitro repair assay, we investigated NER activity of cisplatin‐induced DNA lesions in a panel of 16 non‐small cell lung cancer (NSCLC) cell lines. The interrelationships between NER activity, cisplatin sensitivity, HER‐2/neu expression and EGFR level, were also analyzed. The results showed that high NER activity was closely correlated with cisplatin resistance and high levels of HER‐2/neu expression (P < 0.05). Analysis of the relationships between EGFR level and each of the other three parameters revealed no statistically significant correlations (all P values were > 0.05 by Spearman rank correlation), but a trend of association (all the values of proportion of accordance were ≥62.5% by using a 2x2 contingency table). These results suggest that NER activity may play an important role in the cisplatin resistance of NSCLC cells and there may be an association between enhanced NER activity and high levels of p185neu and probably EGFR in NSCLC cells. The finding that high levels of EGFR showed very little influence on the relationship between p185neu and cisplatin resistance suggests that EGFR may be a less crucial factor in modulating the chemoresistance of NSCLC cells when compared with HER‐2/neu.

Keywords: Nucleotide excision repair, Cisplatin resistance, Epidermal growth factor receptor, HER‐2/neu, Non‐small cell lung cancer

Full Text

The Full Text of this article is available as a PDF (219.0 KB).

REFERENCES

  • 1. ) Parsons , J. T. and Parsons , S. J.Protein‐tyrosine kinases, oncogenes, and cancer . In“Important Advances in Oncology ,” ed. DeVita V. T., Jr. , Hellman S. and Rosenberg S. A. , pp. 3 – 18 ( 1993. ). J. B. Lippincott Co. , Philadelphia . [PubMed] [Google Scholar]
  • 2. ) Hynes , N. E. and Stern , D. F.The biology of erbB‐2/neu/ HER‐2 and its role in cancer . Biochim. Biophys. Acta , 1198 , 165 – 184 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Tateishi , M. , Ishida , T. , Mitsudomi , T. , Kaneko , S. and Sugimachi , K.Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung . Cancer Res. , 50 , 7077 – 7080 ( 1990. ). [PubMed] [Google Scholar]
  • 4. ) Kameda , T. , Yasui , W. , Yoshida , K. , Tsujino , T. , Nakayama , H. , Ito , M. , Ito , H. and Tahara , E.Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification . Cancer Res. , 50 , 8002 – 8009 ( 1990. ). [PubMed] [Google Scholar]
  • 5. ) Schneider , P. M. , Hung , M. C. , Chiocca , S. M. , Manning , J. , Zhao , X. , Fang , K. and Roth , J. A.Differential expression of the c‐erbB‐2 gene in human small cell and nonsmall cell lung cancer . Cancer Res. , 49 , 4968 – 4971 ( 1989. ). [PubMed] [Google Scholar]
  • 6. ) Arteaga , C. L.Epidermal growth factor receptors and erbB‐2 in human lung cancer . In“Lung Cancer: Principles and Practice ,” ed. Pass H. J. , Mitchell J. B. , Johnson D. H. and Turrisi A. T. , pp. 99 – 106 ( 1996. ). Lippincott‐Raven Publ. , Philadelphia . [Google Scholar]
  • 7. ) Maurizi , M. , Scambia , G. , Benedetti‐Panici , P. , Ferrandina , G. , Almadori , G. , Paludetti , G. , De Vincenzo , R. , Distefano , M. , Brinchi , D. , Cadoni , G. and Mancuso , S.EGF receptor expression in primary laryngeal cancer: correlation with clinicopathological features and prognostic significance . Int. J. Cancer , 52 , 862 – 866 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Neal , D. E. , Marsh , C. and Bennett , M. K.Epidermal growth factor receptors in human bladder cancer: comparison of invasive and superficial tumors . Lancet , i , 366 – 368 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Sainsbury , J. R. C. , Farndon , J. R. , Needham , G. K. , Malcolm , A. J. and Harris , A. L.Epidermal growth factor receptor status as predictor of early recurrence of and death from breast cancer . Lancet , i , 1398 – 1402 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Scambia , G. , Benedetti‐Panici , P. , Ferrandina , G. , Battaglia , F. , Distefano , M. , D'andrea , G. , De Vincenzo , R. , Maneschi , F. , Ranelletti , F. O. and Mancuso , S.Significance of epidermal growth factor receptor expression in primary human endometrial cancer . Int. J. Cancer , 56 , 26 – 30 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Scambia , G. , Benedetti‐Panici , P. , Distefano , M. , Salerno , G. , Romanini , M. E. , Fagotti , A. and Mancuso , S.Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy . Br. J. Cancer , 72 , 361 – 366 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. ) Slamon , D. J. , Godolphin , W. , Jones , L. A. , Holt , J. A. , Wong , S. G. , Keith , D. E. , Levin , W. J. , Stuart , S. G. , Udove , J. , Ullrich , A. and Press , M.Studies of the HER‐2/neu proto‐oncogene in human breast and ovarian cancer . Science , 244 , 707 – 712 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 13. ) Kern , J. A. , Schwartz , D. A. , Nordberg , J. E. , Weiner , D. B. , Greene , M. I. , Torney , L. and Robinson , R. A.p185neu expression in human lung adenocarcinomas predicts shortened survival . Cancer Res. , 50 , 5184 – 5191 ( 1990. ). [PubMed] [Google Scholar]
  • 14. ) Tateishi , M. , Ishida , T. , Mitsudomi , T. , Kaneko , S. and Sugimachi , K.Prognostic value of c‐erbB‐2 protein expression in human lung adenocarcinoma and squamous cell carcinoma . Eur. J. Cancer , 27 , 1372 – 1375 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Allred , D. C. , Clark , G. M. , Tandon , A. K. , Molina , R. , Tormey , D. C. , Osborne , C. K. , Gilchrist , K. W. , Mansour , E. G. , Abeloff , M. , Eudey , L. and McGuire , W. L. J.HER2/neu in node‐negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma . J. Clin. Oncol. , 10 , 599 – 605 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Tsai , C. M. , Chang , K. T. , Perng , R. P. , Mitsudomi , T. , Chen , M. H. , Kadoyama , C. and Gazdar , A. F.Correlation of intrinsic chemoresistance of non‐small cell lung cancer cell lines with HER‐2/neu gene expression but not with ras gene mutations . J. Natl. Cancer Inst. , 85 , 897 – 901 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Tsai , C. M. , Chang , K. T. , Wu , L. H. , Chen , J. Y. , Gazdar , A. F. , Mitsudomi , T. , Chen , M. H. and Perng , R. P.Correlations between intrinsic chemoresistance and HER‐2/neu gene expression, p53 gene mutations and cell proliferation characteristics in non‐small cell lung cancer cell lines . Cancer Res. , 56 , 206 – 209 ( 1996. ). [PubMed] [Google Scholar]
  • 18. ) Tsai , C. M. , Yu , D. , Chang , K. T. , Wu , L. H. , Perng , R. P. , Ibrahim , N. K. and Hung , M. C.Enhanced chemoresistance by elevation of the levels of p185neu in the HER‐2/neu transfected human lung cancer cells . J. Natl. Cancer Inst. , 87 , 682 – 684 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Yu , D. , Liu , B. , Tan , M. , Li , J. , Wang , S. S. and Hung , M. C.Overexpression of c‐erbB‐2/neu in breast cancer cells confers increased resistance to Taxol via mdr‐l‐independent mechanisms . Oncogene , 13 , 1359 – 1365 ( 1996. ). [PubMed] [Google Scholar]
  • 20. ) Benz , C. C. , Scott , G. K. , Sarup , J. C. , Johnson , R. M. , Tripathy , D. , Coronado , E. , Shepard , H. M. and Osborne , C. K.Estrogen‐dependent, tamoxifen‐resistant tumorigenic growth of MCF‐7 cells transfected with HER2/neu . Breast Cancer Res. Treat. , 24 , 85 – 95 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Alaoui‐Jamali , M. A. , Paterson , J. , Moustafa , A. I. and Yen , L.The role of ErbB‐2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications . Biochem. Cell Biol. , 75 , 315 – 325 ( 1997. ). [PubMed] [Google Scholar]
  • 22. ) Tsai , C. M. , Levitzki , A. , Wu , L. H. , Chang , K. T. , Cheng , C. C. , Gazit , A. and Perng , R. P.Enhancement of chemosensitivity by tyrphostin AG825 in high p185neu expressing non‐small cell lung cancer cells . Cancer Res. , 56 , 1068 – 1074 ( 1996. ). [PubMed] [Google Scholar]
  • 23. ) Zhang , L. and Hung , M. C.Sensitization of HER‐2/neu overexpressing non‐small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin . Oncogene , 12 , 571 – 576 ( 1996. ). [PubMed] [Google Scholar]
  • 24. ) Hancock , M. C. , Langton , B. C. , Chan , T. , Toy , P. , Monahan , J. J. , Mischak , R. P. and Shawver , L. K.A monoclonal antibody against the c‐erbB‐2 protein enhances the cytotoxicity of cis‐diamminedichloroplatinum against human breast and ovarian tumor cell lines . Cancer Res. , 51 , 4575 – 4580 ( 1991. ). [PubMed] [Google Scholar]
  • 25. ) Pietras , R. J. , Fendly , B. M. , Chazin , V. R. , Pegrum , M. D. , Howell , S. B. and Slamon , D. J.Antibody to HER‐2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells . Oncogene , 9 , 1829 – 1838 ( 1994. ). [PubMed] [Google Scholar]
  • 26. ) Arteaga , C. L. , Winnier , A. R. , Poirier , M. C. , Lopez‐Larraza , D. M. , Shawver , L. K. , Hurd , S. D. and Stewart , S.J. p185c‐erbB‐2 signaling enhances cisplatin‐induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and druginduced DNA repair . Cancer Res. , 54 , 3758 – 3765 ( 1994. ). [PubMed] [Google Scholar]
  • 27. ) Yen , L. , Nie , Z. R. , You , X. L. , Richard , S. , Langton‐Webster , B. C. and Alaoui‐Jamali , M. A.Regulation of cellular response to cisplatin‐induced DNA damage and DNA repair in cells overexpressing p185(erbB‐2) is dependent on the ras signaling pathway . Oncogene , 14 , 1827 – 1835 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 28. ) Tsai , C. M. , Perng , R. P. , Chen , M. H. , Jan , Y. H. , Hung , M. C. , Ku , T. Y. and Chang , K. T.Greater enhancement of chemosensitivity by caffeine in high p185neu expressing human non‐small cell lung cancer cell lines . J. Natl. Cancer Inst. , 86 , 1018 – 1020 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 29. ) Tsai , C. M. , Chang , K. T. , Chen , J. Y. , Chen , Y. M. , Chen , M. H. and Perng , R. P.The cytotoxic effects of gemcitabine‐containing regimens against human non‐small cell lung cancer cell lines which express different levels of p185neu . Cancer Res. , 56 , 794 – 801 ( 1996. ). [PubMed] [Google Scholar]
  • 30. ) Pegram , M. D. , Finn , R. S. , Arzoo , K. , Beryt , M. , Pietras , R. J. and Slamon , D. J.The effect of HER‐2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells . Oncogene , 15 , 537 – 547 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 31. ) Christen , R. D. , Hem , D. K. , Porter , D. C. , Andrews , P. A. , MacLeod , C. L. , Hafstrom , L. and Howell , S. B.Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin . J. Clin. Invest. , 86 , 1632 – 1640 ( 1990. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. ) Kroning , R. , Jones , J. A. , Hom , D. K. , Chuang , C. C. , Sanga , R. , Los , G. , Howell , S. B. and Christen , R. D.Enhancement of drug sensitivity of human malignancies by epidermal growth factor . Br. J. Cancer , 72 , 615 – 619 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. ) Dixit , M. , Yang , J. L. , Poirier , M. C. , Price , J. O. , Andrews , P. A. and Arteaga , C. L.Abrogation of cisplatin‐induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA . J. Natl. Cancer Inst. , 89 , 365 – 373 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 34. ) Dickstein , B. M. , Wosikowski , K. and Bates , S. E.Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor . Mol. Cell. Endocrinol. , 110 , 205 – 211 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 35. ) Fan , Z. , Baselga , J. , Masui , H. and Mendelsohn , J.Antitumor effect of anti‐epidermal growth factor receptor monoclonal antibodies plus cis‐diamminedichloraplatinum on well established A431 cell xenografts . Cancer Res. , 53 , 4637 – 4642 ( 1993. ). [PubMed] [Google Scholar]
  • 36. ) Baselga , J. , Norton , L. , Masui , H. , Pandiella , A. , Coplan , K. , Miller , W. H. , Jr. and Mendelsohn , J.Antitumor effects of doxorubicin in combination with anti‐epidermal growth factor receptor monoclonal antibodies . J. Natl. Cancer Inst. , 85 , 1327 – 1333 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 37. ) Aghajanian , C. , Zhuo , Y. , Ho , T. Y. , Brown , C. , Fan , Z. , Baselga , J. , Mendelsohn , J. and Spriggs , D. R.Anti‐epidermal growth factor receptor monoclonal antibody treatment of A431 cells decreases cisplatin/DNA adduct repair in association with NF‐KB induction [abstract] . Proc. Am. Assoc. Cancer Res. , 36 , 427 ( 1995. ). [Google Scholar]
  • 38. ) Coussens , L. , Yang‐Feng , T. L. , Liao , Y. C. , Chen , E. , Gray , A. , McGrath , J. , Seeburg , P. H. , Libermann , T. , Schlessinger , J. , Francke , U. , Levinson , A. and Ullrich , A.Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene . Science , 230 , 1132 – 1139 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 39. ) Wen , D. , Suggs , S. V. , Karunagaran , D. and Liu , N.Structural and functional aspects of the multiplicity of Neu differentiation factors . Mol. Cell. Biol. , 14 , 1909 – 1919 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. ) Peles , E. and Yarden , Y.Neu and its ligands: from an oncogene to neural factors . BioEssays , 15 , 815 – 824 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 41. ) Stern , D. F. and Kamps , M. P.EGF‐stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions . EMBO J. , 7 , 995 – 1001 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. ) Johnson , G. , Kannan , B. , Shoyab , M. and Stromberg , K.Amphiregulin induces tyrosine phosphorylation of the epidermal growth factor receptor and p185erbB2 . J. Biol. Chem. , 268 , 2924 – 2931 ( 1993. ). [PubMed] [Google Scholar]
  • 43. ) Goldman , R. , Ben Levy , R. , Peles , E. and Yarden , Y.Heterodimerization of the erbB‐1 and erbB‐2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation . Biochemistry , 29 , 11024 – 11028 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 44. ) Spivak‐Kroizman , T. , Rotin , D. , Pinchasi , D. , Ullrich , A. , Schlessinger , J. and Lax , I.Heterodimerization of c‐erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses . J. Biol. Chem. , 267 , 8056 – 8063 ( 1992. ). [PubMed] [Google Scholar]
  • 45. ) Kokai , Y. , Meyers , J. N. , Wada , T. , Brown , V. I. , LeVea , C. M. , Davis , J. G. , Dobashi , K. and Greene , M. I.Synergistic interaction of p185c‐neu, and the EGF receptor leads to transformation of rodent fibroblasts . Cell , 58 , 287 – 292 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 46. ) Zamble , D. and Lippard , S. J.Cisplatin and DNA repair in cancer chemotherapy . Trends Biochem. Sci. , 20 , 435 – 439 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 47. ) Huang , J. C. , Zamble , D. B. , Reardon , J. T. , Lippard , S. J. and Sancar , A.HMG‐domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease . Proc. Natl. Acad. Sci. USA , 91 , 10394 – 10398 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. ) Hansson , J. and Wood , R. D.Repair synthesis by human cell extracts in DNA damaged by cis‐ and trans‐diamminedichloroplatinum (II) . Nucleic Acids Res. , 20 , 8073 – 8091 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. ) Li , L. , Liu , X. , Glassman , A. B. , Keating , M. J. , Stros , M. , Plunkett , W. and Yang , L. Y.Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin‐induced DNA adducts in vitro . Cancer Res. , 57 , 1487 – 1494 ( 1997. ). [PubMed] [Google Scholar]
  • 50. ) Manley , J. L. , Fire , A. , Samuels , M. and Sharp , P. A.In vitro transcription: whole cell extract . Methods Enzymol. , 101 , 568 – 582 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 51. ) Shivji , M. K. K. , Podust , V. N. , Hubscher , U. and Wood , R. D.Nucleotide excision repair DNA synthesis by DNA polymerase ∈ in the presence of PCNA, RFC, and RPA . Biochemistry , 34 , 5011 – 5017 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 52. ) Zeng‐Rong , X. , Paterson , J. , Alpert , L. , Tsao , M. S. , Viallet , J. and Alaoui‐Jamali , M. A.Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy . Cancer Res. , 55 , 4760 – 4764 ( 1995. ). [PubMed] [Google Scholar]
  • 53. ) Tsai , C. M. , Chang , K. T. , Perng , R. P. and Chen , J. Y.Epidermal growth factor modulates chemosensitivity of non‐small cell lung cancer cells through its effect on cell proliferation . Proc. Am. Assoc. Cancer Res. , 38 , 195 ( 1997. ). [Google Scholar]
  • 54. ) Weidner , U. , Peter , S. , Strohmeyer , T. , Hussnatter , R. , Ackermann , R. and Sies , H.Inverse relationship of epidermal growth factor receptor and HER‐2/neu, gene expression in human renal cell carcinoma . Cancer Res. , 50 , 4504 – 4509 ( 1990. ). [PubMed] [Google Scholar]
  • 55. ) Fisher , D. E.Apoptosis in cancer therapy: crossing the threshold . Cell , 78 , 539 – 542 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 56. ) Liebermann , D. A. , Hoffman , B. and Steinman , R. A.Molecular controls of growth arrest and apoptosis: p53‐dependent and independent pathways . Oncogene , 11 , 199 – 210 ( 1995. ). [PubMed] [Google Scholar]
  • 57. ) Vaux , D. L. and Strasser , A.The molecular biology of apoptosis . Proc. Natl. Acad. Sci. USA , 93 , 2239 – 2244 ( 1996. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. ) Yu , D. , Jing , T. , Liu , B. , Yao , J. , Tan , M. , McDonnell , T. J. and Hung , M. C.Overexpression of erbB2 blocks taxolinduced apoptosis by upregulation of p21cipl, which inhibits p34cdc2 kinases . Mol. Cell , 2 , 581 – 591 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 59. ) Volm , M. , Kastel , M. , Mattern , J. and Efferth , T.Expression of resistance factors (P‐glycoprotein, glutathione Stransferase‐pi, and topoisomerase II) and their interrelationship to proto‐oncogene products in renal cell carcinomas . Cancer , 71 , 3981 – 3987 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 60. ) Yang , J. M. , Sullivan , G. F. and Hait , W. N.Regulation of the function of P‐glycoprotein by epidermal growth factor through phospholipase C . Biochem. Pharmacol. , 53 , 1597 – 1604 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 61. ) Allen , G. C. , Lubas , S. , Wax , M. K. and Devore , R. F. , III Epidermal growth factor regulates topoisomerase II activity and drug sensitivity in human KB cells . Otolaryngol. Head Neck Surg. , 114 , 785 – 792 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 62. ) Slamon , D. , Leyland‐Jones , B. , Shak , S. , Paton , V. , Bajamonde , A. , Fleming , T. , Fiermann , W. , Wolter , J. , Baselga , J. and Norton , L.Addition of Herceptin (humanized anti‐HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial . Proc. Am. Soc. Clin. Oncol. , 17 , 98a ( 1998. ). [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES